2. Academic Validation
  3. Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide

Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide

  • Int J Appl Basic Med Res. 2023 Apr-Jun;13(2):106-112. doi: 10.4103/ijabmr.ijabmr_58_23.
Shiba Ansari 1,  Madeeha Mudassir 2,  B Vijayalekshmi 3,  Parthaprasad Chattopadhyay 4
Affiliations

Affiliations

  • 1 Department of Biochemistry, University College of Medical Sciences, Delhi, India.
  • 2 Department of Obstetrics and Gynecology, University College of Medical Sciences and Guru Tegh Bahadur Hospital, Delhi, India.
  • 3 Division of GI Sciences, Wellcome Trust Research Laboratory, Christian Medical College, Vellore, Tamil Nadu, India.
  • 4 Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
PMID: 37614837 DOI: 10.4103/ijabmr.ijabmr_58_23
Abstract

Background: Chemokine Receptor CXCR4 is frequently present in cells of various cancers. Hence, targeted therapy using CXCR4 ligands, such as DV1 peptide, on drug-loaded nanoparticles, has the potential to enhance the efficiency of Cancer treatment.

Aim: The present study created a CXCR4-targeting drug delivery system using avidin-poly (lactic-co-glycolic acid) (PLGA) nanoparticle surface tagged with biotinylated DV1 peptide ligand.

Materials and methods: A double-emulsion solvent evaporation technique was employed to prepare avidin-PLGA nanoparticles and characterized by transmission electron microscopy (TEM) and dynamic light scattering. Uptake was studied by confocal microscopy after incorporating fluorescein isothiocyanate (FITC)-labeled albumin inside the nanoparticles during their synthesis. Peptide-biotin-avidin-PLGA nanoparticles were tested in vitro on CXCR4-expressing U87MG cells. Photomicroscopy was done by a Nikon A1 Confocal Microscope, and pictures were analyzed by Nikon NIS-Elements BR software.

Results: Experimental results confirmed the specificity of DV1 peptide-tagged avidin-PLGA nanoparticles for cells expressing CXCR4 receptors. The avidin-PLGA nanoparticles were successfully synthesized and the same was confirmed by tagging them with FITC-labeled biotin.

Conclusion: Avidin-PLGA nanoparticle surface tagged with biotinylated DV1 peptide ligand has potential clinical application in the treatment of various cancers as targeted therapy for CXCR4-expressing Cancer cells.

Keywords

CXCR4 receptors; Cancer therapeutics; DV1 peptide; poly(lactic-co-glycolic acid) nanoparticles.

Figures
Products